Samrat Pharmachem Limited (BOM:530125)

India flag India · Delayed Price · Currency is INR
211.50
+1.55 (0.74%)
At close: Apr 28, 2026
-43.85%
Market Cap 649.45M
Revenue (ttm) 2.89B
Net Income (ttm) -16.75M
Shares Out 3.09M
EPS (ttm) -5.42
PE Ratio n/a
Forward PE n/a
Dividend 1.00 (0.47%)
Ex-Dividend Date Sep 18, 2025
Volume 1,720
Average Volume 1,875
Open 214.95
Previous Close 209.95
Day's Range 205.00 - 214.95
52-Week Range 190.00 - 420.00
Beta -0.35
RSI 48.07
Earnings Date May 30, 2026

About Samrat Pharmachem

Samrat Pharmachem Limited engages in the manufacture and sale of pharmaceutical chemicals in India. It offers 3-5-di iodosalicylic acid, ammonium iodide, cadmium iodide, calcium iodate, clioquinol, copper iodide, ethyl iodide, ethylenediamine dihydroiodide, hydroiodic acid, iodine, iodine monochloride, iodoquinol, methyl iodide, n-iodo succinimide, periodic acid, potassium iodate and iodide, potassium metaper iodate, povidone iodine, sodium iodate and iodide, and sodium metaper iodate. The company serves the agrochemical, animal feed, chemical,... [Read more]

Industry Industrial Inorganic Chemicals
Founded 1992
Employees 28
Stock Exchange Bombay Stock Exchange
Ticker Symbol 530125
Full Company Profile

Financial Performance

In fiscal year 2025, Samrat Pharmachem's revenue was 2.86 billion, an increase of 1.52% compared to the previous year's 2.82 billion. Earnings were 71.12 million, an increase of 228.87%.

Financial Statements

News

There is no news available yet.